Jubilant Pharmova Ltd.

Financial

	Jubilant Pharmova	Caplin Point Lab	Natco Pharma
Operational Metrics
Pharmaceutical Sector
Australia DMF fillings	14.0 .	n/a	n/a
Number of ANDA's Filed in Europe	38.0	n/a	n/a
Number of ANDA's Approved in Europe	37.0	n/a	n/a
Number of ANDA's Filed in Canada	24.0	n/a	n/a
Number of ANDA's Approved by Canada	24.0	n/a	n/a
Number of ANDA's Filed in USA	100.0 .	51.0 .	51.0 .
Number of ANDA's Approved By USFDA	62.0 .	38.0 .	41.0 .
US DMF Filings	98.0 .	n/a	58.0 .
Canada DMF fillings	42.0 .	n/a	n/a
Japan DMF Filings	15.0 .	n/a	n/a
R&D as a % of Total Sales	0.18 %	4.6 %	7.6 %
Financials
5 yr Average ROE	7.82 %	20.61 %	13.06 %
5yr average Equity Multiplier	1.96	1.17	1.18
5yr Average Asset Turnover Ratio	0.61	0.72	0.46
5yr Avg Net Profit Margin	6.45 %	24.8 %	23.09 %
Price to Book	2.69	5.69	2.06
P/E	36.54	28.7	9.23
5yr Avg Cash Conversion Cycle	-39.98 Days	79.85 Days	10.54 Days
Inventory Days	74.06 Days	64.55 Days	99.95 Days
Days Receivable	45.59 Days	100.92 Days	86.16 Days
Days Payable	149.89 Days	74.04 Days	154.15 Days
5yr Average Interest Coverage Ratio	3.78	579.71	46.61
5yr Avg ROCE	8.15 %	25.27 %	16.05 %
5yr Avg Operating Profit Margin	16.76 %	30.87 %	30.17 %
5 yr average Debt to Equity	0.55	0.01	0.06
5yr CAGR Net Profit	0.08 %	16.28 %	24.68 %
5yr Average Return on Assets	4.12 %	17.7 %	11.07 %
Shareholdings
Promoter Holding	47.68 %	70.56 %	49.56 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-3.0 %	1.68 %	0.76 %
Change in Mutual Fund Holding (3 Yrs)	5.97 %	0.87 %	-4.64 %

Business

	Jubilant Pharmova	Caplin Point Lab	Natco Pharma
Product Wise Break-Up	Product Wise Break-Up Radiopharmaceuticals 44.9 Contract Manufacturing 16.81 Solid dosage formulations 10.82 Anti-allergic 10.21 Active Pharmaceutical Ingredient (API) 9.26 Contract Research and Development Services 6.7 India branded pharmaceuticals 0.72 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Branded Generic 0 Generic 0 Crop Health 0 API(Domestic & Exports) 0 Formulation 0 Others 0.58	Product Wise Break-Up Formulation 0 Anti-allergic 0 India branded pharmaceuticals 0 Nutritional products 0 Branded Generics 25.0 Radiopharmaceuticals 0 0 Life science chemicals 0 API(Domestic & Exports) 0 Solid dosage formulations 0 Active Pharmaceutical Ingredient (API) 0 Formulations 75.0 Specialty intermediates 0 Crop Health 0 Contract Manufacturing 0	Product Wise Break-Up Formulations 89.5 Anti-allergic 0 India branded pharmaceuticals 0 Nutritional products 0 Branded Generic 0 Radiopharmaceuticals 0 0 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 3.6 Solid dosage formulations 0 Active Pharmaceutical Ingredient (API) 0 Generic 0 Specialty intermediates 0 Crop Protection 1.2 Contract Manufacturing 0 Others 5.7
Segment Break-Up	Segment Break-Up Radiopharma 45.67 CDMO Sterile Injectables 18.99 Drug discovery and development solutions 17.52 Allergy Immunotherapy 9.79 Generics 8.03 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0	-	Segment Break-Up Pharmaceuticals 98.77 Proprietary Novel Drugs 0 CDMO Sterile Injectables 0 0 Allergy Immunotherapy 0 Radiopharma 0 Generics 0 Life Science Ingredients 0 Agrochemicals 1.23
Location Wise Break-Up	Location Wise Break-Up Americas and Europe 90.17 Rest of the World 7.5 India 2.33 China 0 USA 0 Africa 0 LATAM 0	Location Wise Break-Up Africa 6.0 Rest of the World 0 Americas and Europe 0 USA 18.0 China 0 Latin America 76.0 India 0	Location Wise Break-Up Africa 0 Rest of the World 15.24 Americas and Europe 0 USA 70.49 China 0 LATAM 0 India 14.27
Operating Profit Break-Up	Operating Profit Break-Up Radiopharma 32.37 Allergy Immunotherapy 26.93 CDMO Sterile Injectables 23.64 Contract Research and Development 17.05 Generics 0 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0 Others 0.01	-	Operating Profit Break-Up Pharmaceuticals 100.0 Proprietary Novel Drugs 0 CDMO Sterile Injectables 0 Allergy Immunotherapy 0 Radiopharma 0 Generics 0 Contract Research and Development 0 Life Science Ingredients 0 Agrochemicals 0
Capex	Capex CDMO 58.69 Radiopharma 20.6 Contract Research and Development 15.56 Generics 2.12 Allergy Immunotherapy 1.54 Proprietary Novel Drugs 1.49 Life Science Ingredients 0	-	-
Asset Break-Up	Asset Break-Up Contract Research and Development 13.69 Proprietary Novel Drugs 2.12 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0 Others 84.19	-	Asset Break-Up Pharmaceuticals 95.22 Proprietary Novel Drugs 0 Contract Research and Development 0 Life Science Ingredients 0 Agrochemicals 4.78

Jubilant Pharmova Ltd.

SIGN UP FOR FREE